welcome
TipRanks

TipRanks

Health

Health

Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed

TipRanks
Summary
Nutrition label

80% Informative

Morgan Stanley analyst David Bailey keeps an Overweight rating on ResMed (RMD) with a $ 286 price target.

Apnimed provided topline results as part of its Phase 3 trial for AD109 , focused on the treatment of obstructive sleep apnea.

Participants treated with AD109 recorded a mean Apnea-Hypopnea Index reduction of 55.6% .

VR Score

72

Informative language

66

Neutral language

71

Article tone

formal

Language

English

Language complexity

60

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

13

https://www.tipranks.com/glossary/d/disclaimer-disclosurehttps://www.tipranks.com/screener/analysts-top-stocks/?type=stockAnalysisLanding&utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/news/the-fly/apnimed-data-brings-competitive-threat-to-resmed-says-rbc-capital?utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/news/labs/new-on-tipranks-company-kpis-a-game-changer-for-smarter-investment-decisions?llf=rss&utm_source=finance.yahoo.com&utm_medium=referralhttps://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/news/ratings/resmeds-growth-potential-highlighted-by-promising-trial-results-and-future-opportunities?utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/glossary/c/contact-editorhttps://www.tipranks.com/compare-stocks/artificial-intelligence?utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/stocks/rmd/forecast?utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/lp/value-newsletter?llf=rss&utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/news/the-fly/resmed-named-sleep-partner-of-the-qatar-airways-british-irish-lions-tour?utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/news/googl-rmd-tipranks-new-ai-analyst-tool-reveals-2-stocks-for-potential-growth?utm_source=finance.yahoo.com&utm_medium=referralhttps://www.tipranks.com/news/ratings/buy-rating-for-resmed-positive-phase-3-trial-results-and-market-conditions-boost-ad109s-appeal?utm_source=finance.yahoo.com&utm_medium=referral

Affiliate links

no affiliate links